drugset / Trial / NCT04126538
Pirfenidone Capsule in Patients With Chronic Kidney Disease G2 and G3a Study on Safety and Pharmacokinetics
Non-randomizedParallel-groupOpen-labelBasic science
Summary
To evaluate the safety and pharmacokinetic characteristics of pirfenidone capsules in chronic kidney disease G2 and G3a patients, and to provide a basis for the phase II clinical trial program
Timeline
- Start
- 2019-08-27
- Primary completion
- 2021-11-25
- Completion
- 2022-06-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pirfenidone | Small molecule | 400 mg | Oral |